Small cell lung cancer
Conditions
Interventions
Adebrelimab+carboplatin+etoposide/Adebrelimab+cisplatin+etoposide/Adebrelimab+etoposide/Adebrelimab+others:None
Sponsors
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients with extensive stage SCLC diagnosed by pathology 2.Patients must be =18 years 3.Have not received systemic treatment for diagnosis of ES-SCLC before 4.Patients received at least once Adebrelimab
Exclusion criteria
Exclusion criteria: 1.Receiving immuno-oncology therapy or other therapies; 2.Patient is currently participating in other Interventional clinical studies; 3.Patients with other malignant tumors 4.Patients with missing key information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Security (occurrence of = Level 3 AE); | — |
Secondary
| Measure | Time frame |
|---|---|
| Efficacy: progression free survival (PFS), overall survival (OS), objective response rate (ORR) Disease Control Rate (DCR);Safety (AE incidence rate, SAE incidence rate); | — |
Countries
China
Contacts
Public ContactJinming Yu
Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences
Outcome results
None listed